Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ715MR)

This product GTTS-WQ715MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ715MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10711MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ10402MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ15264MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ6117MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ9907MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ15034MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ13884MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ15661MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW